Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Feb;73(3):372–376. doi: 10.1038/bjc.1996.63

Comparative study of CA242 and CA19-9 in chronic pancreatitis.

N Furuya 1, S Kawa 1, O Hasebe 1, M Tokoo 1, K Mukawa 1, S Maejima 1, H Oguchi 1
PMCID: PMC2074436  PMID: 8562344

Abstract

CA242 has been proved to be useful in the diagnosis of pancreatic cancer. The aim of the present study was to clarify the mechanisms contributing to the high specificity of CA242 as compared with CA19-9 resulting from scarce serum elevation of this antigen in patients with chronic pancreatitis by correlating serum levels and endoscopic retrograde choledocho-pancreatography (ERCP) findings and by immunohistochemical analysis. Serum CA19-9 levels were significantly elevated in patients with calcification and with main pancreatic duct (MPD) stenosis or obstruction. On the other hand, serum CA242 levels showed no significant elevation in patients with such factors. Even though such pathological conditions were considered to lead to the stagnation of pancreatic juice, serum CA242 levels seemed to be less affected than serum CA19-9 levels. Immunohistochemical studies of chronic pancreatitis tissues revealed that CA242 was expressed less frequently and less intensely than CA19-9, and the difference in expression was more prominent in the centroacinar cells and terminal ductules. From the results of the present study, it is conceivable that CA242 is less influenced by the stagnation of the pancreatic juice than CA19-9 because of the low levels of expression in ductal systems, which results in the release of this antigen into the circulation in lower amounts than that of CA19-9.

Full text

PDF
372

Images in this article

373Figure 1
on p.373
375Figure 4
on p.375

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arends J. W., Verstynen C., Bosman F. T., Hilgers J., Steplewski Z. Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study. Hybridoma. 1983;2(2):219–229. doi: 10.1089/hyb.1983.2.219. [DOI] [PubMed] [Google Scholar]
  2. Banfi G., Zerbi A., Pastori S., Parolini D., Di Carlo V., Bonini P. Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chem. 1993 Mar;39(3):420–423. [PubMed] [Google Scholar]
  3. Del Villano B. C., Brennan S., Brock P., Bucher C., Liu V., McClure M., Rake B., Space S., Westrick B., Schoemaker H. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983 Mar;29(3):549–552. [PubMed] [Google Scholar]
  4. Haglund C., Lindgren J., Roberts P. J., Kuusela P., Nordling S. Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9. Br J Cancer. 1989 Dec;60(6):845–851. doi: 10.1038/bjc.1989.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Haglund C., Lundin J., Kuusela P., Roberts P. J. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer. 1994 Sep;70(3):487–492. doi: 10.1038/bjc.1994.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Johansson C., Nilsson O., Baeckström D., Jansson E. L., Lindholm L. Novel epitopes on the CA50-carrying antigen: chemical and immunochemical studies. Tumour Biol. 1991;12(3):159–170. doi: 10.1159/000217701. [DOI] [PubMed] [Google Scholar]
  7. Johansson C., Nilsson O., Lindholm L. Comparison of serological expression of different epitopes on the CA50-carrying antigen CanAg. Int J Cancer. 1991 Jul 9;48(5):757–763. doi: 10.1002/ijc.2910480521. [DOI] [PubMed] [Google Scholar]
  8. Kawa S., Tokoo M., Hasebe O., Hayashi K., Imai H., Oguchi H., Kiyosawa K., Furuta S., Homma T. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Br J Cancer. 1994 Sep;70(3):481–486. doi: 10.1038/bjc.1994.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kawa S., Tokoo M., Oguchi H., Furuta S., Homma T., Hasegawa Y., Ogata H., Sakata K. Epitope analysis of SPan-1 and DUPAN-2 using synthesized glycoconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose. Pancreas. 1994 Nov;9(6):692–697. doi: 10.1097/00006676-199411000-00003. [DOI] [PubMed] [Google Scholar]
  10. Kobayashi T., Kawa S., Tokoo M., Oguchi H., Kiyosawa K., Furuta S., Kanai M., Homma T. Comparative study of CA-50 (time-resolved fluoroimmunoassay), Span-1, and CA19-9 in the diagnosis of pancreatic cancer. Scand J Gastroenterol. 1991 Jul;26(7):787–797. doi: 10.3109/00365529108998600. [DOI] [PubMed] [Google Scholar]
  11. Kuusela P., Haglund C., Roberts P. J. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer. 1991 Apr;63(4):636–640. doi: 10.1038/bjc.1991.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Magnani J. L., Nilsson B., Brockhaus M., Zopf D., Steplewski Z., Koprowski H., Ginsburg V. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem. 1982 Dec 10;257(23):14365–14369. [PubMed] [Google Scholar]
  13. Malesci A., Tommasini M. A., Bonato C., Bocchia P., Bersani M., Zerbi A., Beretta E., Di Carlo V. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology. 1987 Jan;92(1):60–67. doi: 10.1016/0016-5085(87)90840-7. [DOI] [PubMed] [Google Scholar]
  14. Nilsson O., Johansson C., Glimelius B., Persson B., Nørgaard-Pedersen B., Andrén-Sandberg A., Lindholm L. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9. Br J Cancer. 1992 Feb;65(2):215–221. doi: 10.1038/bjc.1992.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Nilsson O., Månsson J. E., Lindholm L., Holmgren J., Svennerholm L. Sialosyllactotetraosylceramide, a novel ganglioside antigen detected in human carcinomas by a monoclonal antibody. FEBS Lett. 1985 Mar 25;182(2):398–402. doi: 10.1016/0014-5793(85)80341-0. [DOI] [PubMed] [Google Scholar]
  16. Pasanen P. A., Eskelinen M., Partanen K., Pikkarainen P., Penttilä I., Alhava E. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma. Br J Cancer. 1992 May;65(5):731–734. doi: 10.1038/bjc.1992.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Röthlin M. A., Joller H., Largiadèr F. CA 242 is a new tumor marker for pancreatic cancer. Cancer. 1993 Feb 1;71(3):701–707. doi: 10.1002/1097-0142(19930201)71:3<701::aid-cncr2820710308>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  18. Satomura Y., Sawabu N., Takemori Y., Ohta H., Watanabe H., Okai T., Watanabe K., Matsuno H., Konishi F. Expression of various sialylated carbohydrate antigens in malignant and nonmalignant pancreatic tissues. Pancreas. 1991 Jul;6(4):448–458. doi: 10.1097/00006676-199107000-00012. [DOI] [PubMed] [Google Scholar]
  19. Tabuchi Y., Deguchi H., Saitoh Y. Carcinoembryonic antigen and carbohydrate antigen 19-9 levels of peripheral and draining venous blood in colorectal cancer patients. Correlation with histopathologic and immunohistochemical variables. Cancer. 1988 Oct 15;62(8):1605–1613. doi: 10.1002/1097-0142(19881015)62:8<1605::aid-cncr2820620825>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  20. Tatsuta M., Yamamura H., Iishi H., Ichii M., Noguchi S., Yamamoto R., Okuda S. Values of CA 19-9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor. Cancer. 1985 Dec 1;56(11):2669–2673. doi: 10.1002/1097-0142(19851201)56:11<2669::aid-cncr2820561124>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES